Y
301301
vs
S
Shanghai Composite
Over the past 12 months, Yili Chuanning Biotechnology Co Ltd has underperformed Shanghai Composite, delivering a return of -12% compared to the Shanghai Composite's +23% growth.
Stocks Performance
301301 vs Shanghai Composite
Performance Gap
301301 vs Shanghai Composite
Performance By Year
301301 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Yili Chuanning Biotechnology Co Ltd
Glance View
Yili Chuanning Biotechnology Co Ltd has carved its niche in the expansive landscape of the biotechnology industry by capitalizing on a single, astute vision: enhancing human health through innovative bio-based solutions. Established in the heart of China's burgeoning biotech sector, the company has focused on developing and commercializing a range of probiotic and nutritional products. These products cater to an increasingly health-conscious market, both within China and internationally. Through meticulous research and collaboration with leading scientific institutions, Yili Chuanning has positioned itself as a pivotal player in integrating traditional Chinese medicine wisdom with cutting-edge biotechnology. This hybrid approach not only honors its cultural roots but also meets the rigorous demands of modern science. The company thrives financially by engaging in both B2B and B2C markets. On the business-to-business front, Yili Chuanning supplies raw materials and customized solutions to health food manufacturers, leveraging its proprietary strains and formulations. These partnerships are vital, as they provide steady revenue streams and foster expansive growth opportunities. In the consumer market, Yili Chuanning deftly markets its branded health supplements and functional foods, strategically targeting wellness trends and nutritional gaps in the consumer diet. By maintaining a robust distribution network and investing in strategic marketing campaigns, Yili Chuanning ensures its products reach a broad audience, thus fulfilling its mission to improve public health and deliver strong financial performance.
